John D. Diekman , PhD
Founder and Managing Partner

John D. Diekman, Ph.D. is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Dr. Diekman was a Founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. Dr. Diekman currently serves as Chairman of Ambrx as well as on the Boards of Igenica, PhaseRx and Wildcat. Dr. Diekman was formerly a Board Director of Chemdex (IPO 1999), Envoy (acquired by Takeda), Ingenuity (acquired by Qiagen), LJL BioSystems (IPO 1998) and Marcadia (acquired by Roche). He is a Charter Trustee of Princeton University and former Trustee of The California Institute of Technology and also of The Scripps Research Institute, where he served as Chairman. He serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman holds an Honorary Degree of Doctor of Laws from Monash University. Dr. Diekman is based in the Menlo Park, CA office.